Crude alkaloid extract of Rhazya stricta inhibits cell growth and sensitizes human lung cancer cells to cisplatin through induction of apoptosis

there is an urgent need to improve the clinical management of non-small cell lung cancer (nsclc), one of the most frequent causes of cancer-related deaths in men and women worldwide. rhazya stricta, an important medicinal plant used in traditional oriental medicine, possesses anti-oxidant, anti-carcinogenic and free radical scavenging properties. this study was done to explore the potential anticancer activity of a crude alkaloid extract of r. stricta (caers) against the nsclc line a549. caers markedly suppressed the growth of a549 cells and considerably enhanced the anti-proliferative potential of cisplatin. caers-mediated inhibition of a549 cell growth correlated with the induction of apoptosis that was accompanied by numerous morphological changes, dna fragmentation, an increase in the bax/bcl-2 ratio, the release of mitochondrial cytochrome c, activation of caspases 3 and 9 and cleavage of poly(adp-ribose)-polymerase. caers reduced the constitutive expression of anti-apoptotic proteins (bcl-2, bcl-xl, mcl-1 and survivin) and cell cycle regulating proteins (cyclin d1 and c-myc), but enhanced expression of the proapoptotic proteins noxa and bad. these observations indicate that caers induced apoptosis and sensitized nsclc to cisplatin via a mitochondria-mediated apoptotic pathway. these data provide a rationale for using a combination of caers and cddp to treat nsclc and other cddp-resistant tumors.